Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 2;11(10):822. doi: 10.1038/s41419-020-03030-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Oxaliplatin (Oxa) suppressed AFP expression and decreased the distribution of HuR in cytoplasm. Cells were treated with the indicated concentrations of oxaliplatin for 24 h. b Oxaliplatin activated the Fas/FADD apoptotic pathway in AFP-positive HCC cells. c Knocking down Fas expression attenuated oxaliplatin-induced cytotoxicity. Cell growth was determined by a clonogenic assay. Cells were transfected with siFas or a nontarget siRNA and reseeded in a 6-well plate for 12 h. Then, the cells were incubated with oxaliplatin (0.1 μM) for 40 h and allowed to grow into colonies for 14 days. d Knockdown of the AFP gene in HuH7/HepG2 cells resulted change in sensitivity to sorafenib. The AFP gene was knocked down by siRNA and the viability of cells was assessed by MTT assay. e Sorafenib enhanced cytoplasmic HuR levels and suppressed the activation of Fas/FADD in HuH7 and HepG2 cells. Cells were treated with the indicated concentrations of sorafenib for 24 h. f Sorafenib combined with oxaliplatin had a synergistic effect on the induction of apoptosis. Apoptotic cells (%, Q2 + Q4) are reported as the mean ± SD of three replicate experiments. g Combination treatment with sorafenib and oxaliplatin synergistically inhibited HuH7 and HepG2 cell growth. Cells were plated overnight, exposed to sorafenib and oxaliplatin individually or in combination at the indicated concentrations for 40 h and allowed to grow into colonies for 14 days. h Oxaliplatin in the combination treatment reversed the inhibitory effect of sorafenib on Fas/FADD activation. **P < 0.01 and ***P < 0.001.